Results 211 to 220 of about 37,664 (239)

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

, 2021
265Background: Treatment options for cholangiocarcinoma (CCA) after progression on first-line gemcitabine-based therapy are limited.
M. Javle, S. Roychowdhury, R. Kelley, S. Sadeghi, T. Macarulla, D. Waldschmidt, L. Goyal, I. Borbath, A. El-Khoueiry, Weipeng Yong, P. Philip, M. Bitzer, S. Tanasanvimon, Ai Li, A. Pande, S. Shepherd, S. Moran, G. Abou-Alfa   +17 more
semanticscholar   +1 more source

Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.

European Journal of Cancer, 2022
AIM FGFR2 rearrangements have been identified as a novel therapeutic target of biliary tract cancer (BTC). However, reliable prevalence estimates of this molecular alteration and its prognostic role have not been fully elucidated.
M. Rizzato, Stefano Brignola, G. Munari, M. Gatti, V. Dadduzio, C. Borga, F. Bergamo, A. Pellino, Valentina Angerilli, C. Mescoli, M. Guido, J. Rearden, E. Gringeri, U. Cillo, A. D. Dei Tos, V. Zagonel, F. Loupakis, S. Lonardi, M. Fassan   +18 more
semanticscholar   +1 more source

The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations

Clinical Cancer Research
Purpose FGFR2 and FGFR3 show oncogenic activation in many cancer types, often through chromosomal fusion or extracellular domain mutation. FGFR2 and FGFR3 alterations are most prevalent in intrahepatic cholangiocarcinoma (ICC) and bladder cancers ...
E. Balasooriya, Qibiao Wu, H. Ellis, Y. Zhen, B. Norden, R. Corcoran, Adithi Mohan, Eric Martin, Aleksandra Franovic, John Tyhonas, Matthew Lardy, Kathryn B Grandinetti, Robert Pelham, Liliana Soroceanu, V. S. Silveira, N. Bardeesy   +15 more
semanticscholar   +1 more source

Clustering of FGFR2 gene mutations inpatients with Pfeiffer and Crouzon syndromes (FGFR2-associated craniosynostoses)

Cytogenetic and Genome Research, 2000
A cohort of 36 unrelated German patients with craniosynostosis syndromes of the Crouzon and Pfeiffer type were analyzed for FGFR mutations. Mutations in FGFR2 were identified in 25 Crouzon and 5 Pfeiffer syndrome patients, whereas no sequence alterations were found in the remaining patients, even after screening of the relevant parts of FGFR1, FGFR3 ...
W, Kress, H, Collmann, M, Büsse, B, Halliger-Keller, C R, Mueller   +4 more
openaire   +2 more sources

FGFR1 and FGFR2 Mutations in Pfeiffer Syndrome

Journal of Craniofacial Surgery, 2013
Pfeiffer syndrome (PS) (MIM 101600) is one of the most common syndromic forms of craniosynostosis. It is characterized by craniosysnostosis, midface hypoplasia, broad and medially deviated thumbs, and great toes with partial syndactyly of the digits. Here, we described clinical and genetic features of 12 unrelated Thai individuals with PS.
Chayanin, Chokdeemboon, Charan, Mahatumarat, Nond, Rojvachiranonda, Siraprapa, Tongkobpetch, Kanya, Suphapeetiporn, Vorasuk, Shotelersuk   +5 more
openaire   +2 more sources

Cloning and Sequencing of the Rabbit FGFR2 cDN A

DNA Sequence, 2000
(2000). Cloning and Sequencing of the Rabbit FGFR2 cDN A. DNA Sequence: Vol. 11, No. 5, pp. 439-446.
Z W, Yang, M P, Mooney, R E, Ferrell
openaire   +2 more sources

Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway

Oncogene, 2022
Zeng-li Liu, Jialiang Liu, Tianli Chen, Yue Wang, A. Shi, Kangshuai Li, Xing-Guo Li, B. Qiu, Li-jie Zheng, Li-ming Zhao, Lizhuang Shu, Shuo Lian, Shao-hui Huang, Zongli Zhang, Yunfei Xu   +14 more
semanticscholar   +1 more source

FGFR2

1995
M. Jaye, I. Lax, M. Mohammadi, J. Schlessinger   +3 more
openaire   +1 more source

FGFR2 mutations and acne

The Lancet, 1998
openaire   +2 more sources

Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2‐overexpressing tumor

Cancer Science, 2020
Masakazu Yashiro, Atsushi Sugimoto
exaly